Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[68Ga]Ga-DOTA-TATE PET/CT imaging in neuroendocrine neoplasms
NCT06240741Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2024
- Primary completion
- Dec 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gallium ga 68 dotatate in neuroendocrine neoplasms (NENs), sponsored by Novartis. Started Mar 2024; status: completed.
02
Drugs
gallium ga 68 dotatate
03
Conditions
neuroendocrine neoplasms (NENs)
Beyond the preview
Go deeper on NCT06240741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06240741.